Search Bar & Filters
Found 572 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating 4D-150, an AAV-based gene therapy targeting VEGF-C and encoding aflibercept, in adults aged 50 and older with wet age-related macular degeneration AMD who are already receiving active anti-VEGF treatment. This Phase 12 trial includes dose escalation, randomized controlled masked expansion, and several substudies to assess safety, tolerability, and vector shedding. Participants will receive a single intravitreal injection of 4D-150 in the study eye. The trial includes Dose Escalation, Dose Expansion, Steroid Optimization, and Population Extension Cohorts. Some participants may also receive a one-time 4D-150 injection in the contralateral eye as part of a substudy. Aflibercept, a standard anti-VEGF drug, is given in a fixed regimen to control groups. Assessments occur monthly for 24 months, followed by a long-term follow-up up to 5 years to monitor safety and clinical activity. During the study, participants will have monthly evaluations including visual acuity tests using the ETDRS chart and retinal imaging by spectral domain optical coherence tomography SD-OCT. Researchers will track adverse events, need for additional aflibercept injections, and changes in retinal thickness and visual acuity. Safety and tolerability are monitored throughout the 52-week main period and during the extended follow-up. Some participants will also be involved in substudies focused on vector shedding and contralateral eye dosing, with regular safety assessments through week 52 and long-term monitoring through five years.
Actively Recruiting
Researchers are evaluating a new diagnostic imaging agent called 68GaGa DOTA-5G in patients with metastatic or advanced invasive lobular breast cancer LBC. This phase I study aims to determine if 68GaGa DOTA-5G can detect cancer lesions more sensitively than the current standard 18F-FDG PETCT, while also assessing its safety and tolerability. The study plans to enroll 30 patients over 24 months to gather initial data on this imaging approach. Participants will receive an injection of up to 5 mCi of 68GaGa DOTA-5G and undergo PETCT scans at 1 and 2 hours after injection. This imaging process is designed to highlight cancer lesions for evaluation. The study is a single-group design without placebo or comparator arms, focusing on assessing the agents diagnostic capabilities and safety profile. During the study, participants will be monitored for the ability of the imaging to detect lesions within 2 hours of injection and for any adverse events occurring up to 7 days post-injection, using standard safety criteria. Patients must remain still for 30 to 60 minutes during scans. The total participation involves screening, imaging, and follow-up for safety, with the study concluding by June 2027.
Actively Recruiting
This research aims to evaluate the efficacy and safety of rilzabrutinib in adults diagnosed with active Immunoglobulin G4-related disease IgG4-RD. It is a Phase 3, randomized, double-blind, placebo-controlled study that will measure the time to clinical disease flare and other important efficacy and safety outcomes over a 52-week treatment period. The study includes adult participants aged 18 and older who have a confirmed diagnosis of IgG4-RD and active disease in at least one organ. Participants will be randomly assigned to receive either rilzabrutinib tablets or a placebo, both taken orally, over a 52-week double-blind treatment period. The study also includes a screening period of 4 to 6 weeks before treatment, followed by a 2-week follow-up after the treatment phase. An optional open-label extension lasting 108 weeks is available for participants who complete the main study. The total study duration may extend up to 60 weeks for the main phases. Throughout the study, participants will attend up to 16 visits during the main treatment period and additional visits if they join the extension phase. Researchers will monitor disease activity and flare rates using clinical assessments, imaging procedures such as CT, MRI, PET, or ultrasound, laboratory tests, ECGs, and safety evaluations including adverse event monitoring. Outcomes include flare-free rates, disease activity scores, glucocorticoid use, and safety parameters, with follow-up continuing beyond the treatment phase to assess long-term effects.
Actively Recruiting
Researchers are investigating new treatment options for people with locally advanced or metastatic colorectal cancer mCRC that cannot be removed by surgery and has a specific gene mutation called KRAS G12C. The study aims to evaluate the safety and tolerance of combining calderasib, cetuximab, and mFOLFOX6 chemotherapy compared to the standard treatment of mFOLFOX6 with or without bevacizumab. This research is a phase 3 clinical trial focused on improving outcomes for this specific patient group. Participants will be assigned to one of two groups. One group receives calderasib tablets orally, cetuximab every two weeks, and mFOLFOX6 chemotherapy including oxaliplatin, leucovorin or levofolinate calcium, and 5-fluorouracil every two weeks. The other group receives mFOLFOX6 chemotherapy with or without bevacizumab or a bevacizumab biosimilar, also administered every two weeks. Treatment continues until doctors decide to stop based on specific criteria. During the study, participants will be closely monitored for side effects and treatment tolerability, with evaluations lasting up to about 44 months in the first part and up to 5 years in the second part. Researchers will collect data on progression-free survival, response rates, overall survival, and quality of life using various questionnaires. Safety assessments and tracking of any adverse events will be conducted regularly throughout the study.
Actively Recruiting
Researchers are studying ways to prevent cytomegalovirus CMV infection in children and adolescents who have received a kidney transplant and weigh less than 40 kilograms. This trial focuses on understanding how the drug letermovir behaves in the body over time and assessing its safety and tolerance in this young population. The study is a phase 1, open-label, single-arm trial sponsored by Merck Sharp & Dohme LLC. Participants who are between 4 and 52 weeks post-kidney transplant will receive oral letermovir, either as tablets or pellets, or via gastrostomy or nasogastric tube pellets only for 7 consecutive days. The study uses weight-banded dosing to tailor the treatment to each child or adolescents weight. During the study, participants will be closely monitored with blood sampling to measure letermovir levels over a 24-hour period on Day 7. Researchers will also track any adverse events for up to 21 days and note if any participant stops the treatment due to side effects within 7 days. The total study duration for each participant includes the treatment period and safety monitoring, extending until the primary outcome data is collected.
Actively Recruiting
Researchers are investigating new treatments to prevent non-small cell lung cancer NSCLC from returning after surgery in people with high-risk, localized Stage I NSCLC. This Phase 3 randomized clinical trial compares adjuvant intismeran autogene V940 alone or combined with subcutaneous pembrolizumab and berahyaluronidase alfa against placebo in participants who have had their cancer completely removed. The goal is to improve disease-free survival in these patients. Participants are assigned to one of three groups one receives intismeran 1 mg by intramuscular injection plus pembrolizumab with berahyaluronidase alfa by subcutaneous injection another group receives intismeran alone by intramuscular injection and the third group receives a placebo injection. Treatments are given as part of the study, with dosing schedules and combinations designed to evaluate their effects on cancer recurrence. During the study, participants will be closely monitored through regular assessments including imaging scans and laboratory tests to track disease status and side effects. Researchers will measure outcomes such as disease-free survival, distant metastasis-free survival, overall survival, and quality of life using standardized questionnaires. Safety will also be monitored throughout the study, which may last up to several years for some participants.
Actively Recruiting
Researchers are investigating new treatments for neovascular age-related macular degeneration NVAMD, a condition that affects the eye and vision. This trial aims to compare a new medicine called tiespectus also known as MK-8748 or EYE201 with the standard treatment aflibercept to see if tiespectus works as well for people with NVAMD. The study is a randomized, double-masked, pivotal phase 23 trial focusing on treatment effectiveness and safety. Participants will be assigned to one of three groups one receiving a low dose of tiespectus, another receiving a high dose of tiespectus, and a third group receiving aflibercept. In the tiespectus groups, participants will get three initial injections every four weeks, followed by injections every eight weeks until week 48. After week 48, treatment intervals will be personalized based on individual responses, continuing up to week 92. The aflibercept group also receives three initial injections followed by injections every eight weeks until week 92. Throughout the study, participants will have their vision assessed using a standard eye chart to measure changes in best-corrected visual acuity BCVA from the start through one year. Additional measures include eye imaging to assess retinal thickness and monitoring for any side effects or adverse events up to approximately 96 weeks. The trial will last until June 2028, with ongoing monitoring and follow-up visits to evaluate the safety and effectiveness of the treatments.
Actively Recruiting
Researchers are investigating new treatments for diabetic macular edema DME, a condition that can cause vision loss. This trial aims to compare the effects of a new medicine called MK-8748 with the current standard treatment, aflibercept, to see if MK-8748 works as well. The study focuses on adults with type 1 or type 2 diabetes who have vision decrease due to DME. Participants will be randomly assigned to one of three groups two groups receive different doses of MK-8748 via injections into the eye, starting with five doses every 4 weeks, then every 8 weeks until week 48, followed by treatment intervals based on individual response up to week 100. The third group receives aflibercept injections on a similar schedule for up to 100 weeks. The study is double-masked and multicenter, designed to carefully compare these treatments. During the trial, participants will have regular eye examinations, including measurements of visual acuity and retinal thickness, along with imaging tests such as optical coherence tomography and fluorescein angiography. Researchers will monitor changes in vision and eye condition over one to two years, assess treatment safety, and track adverse events and drug levels. The main outcome measured is the change in best-corrected visual acuity after one year of treatment.
Actively Recruiting
Researchers are evaluating the effects of intravitreal remigromig EYE103 in adults with neovascular age-related macular degeneration NVAMD or macular edema following branch retinal vein occlusion BRVO. This randomized, dose-masked Phase 2 study includes four patient groups, comparing low and high doses of remigromig, alone or combined with aflibercept for certain participants. The study aims to assess safety and efficacy of these treatments for these eye conditions. Participants will receive three injections of remigromig into the study eye, spaced four weeks apart. In one group of incomplete responders with NVAMD, aflibercept injections are also given on the first day. Participants are randomized within four cohorts to receive either a low or high dose of remigromig, with some receiving combination therapy. Enrollment and treatment timing are managed by the study sponsor. Throughout the study, participants will return for safety and efficacy assessments at each injection visit and may have additional visits two weeks after injections depending on their group. Assessments include vision tests using the ETDRS chart, eye examinations, and imaging to measure retinal thickness. The main outcome measure is the change in best-corrected visual acuity at 12 weeks. The study concludes with a final visit at week 12, after which safety and effectiveness data will be reviewed.
Actively Recruiting
Researchers are studying the safety and effectiveness of a gene transfer therapy called delandistrogene moxeparvovec in males with Duchenne Muscular Dystrophy DMD, including those who are non-ambulatory. This open-label study is focused on evaluating how well the gene therapy expresses dystrophin protein in the muscles and monitoring any side effects over a period of up to 156 weeks. The study is sponsored by Sarepta Therapeutics, Inc. and targets participants aged 2 years and older with a confirmed diagnosis of DMD. Participants will receive a single intravenous infusion of delandistrogene moxeparvovec on Day 1. The study involves different cohorts, with Cohort 8 currently enrolling non-ambulatory participants who meet specific motor function and steroid use criteria. The therapy aims to deliver the gene using a systemic approach, and participants will be monitored closely for safety and gene expression through various laboratory and clinical assessments. Throughout the study, participants will undergo regular evaluations including laboratory tests, muscle biopsies to measure dystrophin protein levels, and monitoring for adverse events such as liver injury or immune responses. Researchers will track antibody levels to the viral vector used in the gene therapy and assess the presence of the gene product at specific time points, especially at 12 weeks post-infusion. The total duration of participation may last up to 156 weeks, with ongoing safety and efficacy checks throughout this period.
1-10 of 572
1